Kowluru R A, Jirousek M R, Stramm L, Farid N, Engerman R L, Kern T S
Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison 53706-1532, USA.
Diabetes. 1998 Mar;47(3):464-9. doi: 10.2337/diabetes.47.3.464.
In the retinas of diabetic animals, protein kinase C (PKC) activity is elevated, and Na+-K+-ATPase and calcium ATPase activities are subnormal. These abnormalities are also present in another model of diabetic retinopathy, experimental galactosemia. We have investigated the relationship between hyperglycemia-induced abnormalities of PKC and ATPases using a selective inhibitor of beta isoform of PKC (LY333531). Diabetes or experimental galactosemia of 2 months' duration resulted in > 50% elevation of PKC activity in the retina, and administration of LY333531 prevented the elevation. In retinas of the same rats, the LY333531 prevented hyperglycemia-induced decreases of both Na+-K+-ATPase and calcium ATPase activities. Retinal microvessels, the main site of lesions in diabetic retinopathy, likewise showed elevated activity of PKC and inhibition of ATPases in diabetes and in experimental galactosemia, and administration of LY333531 to diabetic animals prevented these abnormalities. PKC activity in sciatic nerves, in contrast, became subnormal in diabetes and experimental galactosemia, and LY333531 had no effect on PKC activity in the sciatic nerve. PKC activity in the cerebral cortex was not affected by diabetes or experimental galactosemia. The results suggest that diabetes-induced reductions in Na+-K+-ATPase and calcium ATPase in the retina are mediated in large part by PKC-beta. The availability of an agent that can normalize the hyperglycemia-induced increase in PKC activity in the retina should facilitate investigation of the role of PKC in the development of diabetic retinopathy.
在糖尿病动物的视网膜中,蛋白激酶C(PKC)活性升高,而钠钾ATP酶和钙ATP酶活性则低于正常水平。这些异常情况在糖尿病性视网膜病变的另一种模型——实验性半乳糖血症中也存在。我们使用PKCβ亚型的选择性抑制剂(LY333531)研究了高血糖诱导的PKC异常与ATP酶之间的关系。持续2个月的糖尿病或实验性半乳糖血症导致视网膜中PKC活性升高超过50%,而给予LY333531可阻止这种升高。在同一只大鼠的视网膜中,LY333531可防止高血糖诱导的钠钾ATP酶和钙ATP酶活性降低。视网膜微血管是糖尿病性视网膜病变的主要病变部位,同样在糖尿病和实验性半乳糖血症中显示出PKC活性升高以及ATP酶受到抑制,给糖尿病动物施用LY333531可预防这些异常情况。相比之下,坐骨神经中的PKC活性在糖尿病和实验性半乳糖血症中变得低于正常水平,并且LY333531对坐骨神经中的PKC活性没有影响。大脑皮层中的PKC活性不受糖尿病或实验性半乳糖血症的影响。结果表明,糖尿病诱导的视网膜中钠钾ATP酶和钙ATP酶的减少在很大程度上是由PKCβ介导的。一种能够使视网膜中高血糖诱导的PKC活性增加正常化的药物的可得性,应有助于研究PKC在糖尿病性视网膜病变发展中的作用。